It has recently been demonstrated that a fluorescein-labelled ghrelin (1–18) probe which binds prostate cancer tissue can be used to distinguish between benign prostatic disease and prostate cancer, and therefore, may be a useful diagnostic tool [20]. The gene discussed is GHRL; the disease is prostate cancer.